Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma by Finotello, Riccardo et al.
J. Comp. Path. 2019, Vol. 170, 1e9 Available online at www.sciencedirect.com
ScienceDirectwww.elsevier.com/locate/jcpaNEOPLASTIC DISEASE
Lipoxygenase-5 Expression in Canine Urinary
Bladder: Normal Urothelium, Cystitis and
Transitional Cell CarcinomaCor
002
httpRiccardo Finotello*, Luca Schiavo*, Lorenzo Ressel†, Ava Frohmader‡,
Paolo Silvestrini* and Ranieri Verin†
*Department of Small Animal Clinical Science, †Department of Veterinary Pathology and Public Health, Institute of




Transitional cell carcinoma (TCC) is the most common canine urinary tract tumour and mimics human inva-
sive TCC. Human TCCs overexpress lipoxygenase (LOX)-5 and the use of target inhibitors has proven effec-
tive in inhibiting neoplastic growth. In this study, we investigated the immunohistochemical expression of
LOX-5 in normal canine urinary bladder, cystitis and TCC. The comparative expression of LOX-5, cyclo-
oxygenase (COX)-1 and COX-2 among the three tissue groups was also examined. Biopsy samples from cases
of cystitis and TCC were reviewed from 2012 to 2016; samples of histologically normal bladder were used as
controls. Dogs were excluded if they had received glucocorticoids, non-steroidal anti-inflammatory drugs
(NSAIDs) and/or chemotherapy prior to tissue collection. LOX-5 was expressed in 95% of TCCs, 23% of cases
of cystitis and 10% of controls. LOX-5 and COX-2 immunohistochemistry scores were significantly (P<0.01)
higher in TCCs versus cystitis and normal bladders. Results of this study support the rationale for further inves-
tigation of the use of NSAIDs with dual anti COX-2 and LOX-5 effect for the treatment of canine TCC.
 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: cystitis; dog; lipoxygenase; transitional cell carcinomaIntroduction
Tumours of the urinary bladder account for 2% of all
malignant tumours in dogs, with almost 90% being
malignant and of epithelial origin (Knapp et al.,
2014; Meuten and Meuten, 2017). Transitional cell
carcinoma (TCC), also referred to as urothelial
carcinoma, is known to be the most common
(75e90%) of these neoplasms with the majority of
TCCs (>90% of cases) having an intermediate or
high histological grade and showing an invasive
behaviour (Valli et al., 1995; Anderson et al., 2002;
Patrick et al., 2006).ondence to: (e-mail: riccardofi@libero.it).
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CC BY-NC-NThe treatment of canine TCC can include surgery,
radiation therapy and/or chemotherapy; however,
the latter is used most commonly (Knapp et al.,
2014). Most TCCs are not amenable to surgery due
to the presence of multiple lesions and their common
trigone location; radiation therapy is not commonly
advised as initial investigations have been discour-
aging due to the high incidence of side-effects; howev-
er, newer approaches have provided better results
(Anderson et al., 2002; Poirier et al., 2004; Nolan
et al., 2012; Knapp et al., 2014). Despite being the
most common treatment, chemotherapy provides
only poor to modest responses (0e58%) (Knapp
et al., 2014). To date, the combination of cisplatin
and piroxicam remains probably the most effective
(71% objective response); however, this protocoluthors. Published by Elsevier Ltd. This is an open access article under the
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 R. Finotello et al.does carry a relatively high-risk of renal toxicity
(Greene et al., 2007; Knapp et al., 2013). Piroxicam
is a non-selective cyclooxygenase (COX) inhibitor,
which has shown antineoplastic effect as a single agent
and provided significant advantages when combined
with standard antineoplastic agents (Knapp et al.,
1994, 2014). The drug’s main antineoplastic effects
are believed to occur through inhibition of COX-2,
which is overexpressed in canine TCCs when
compared with normal urothelium (Khan et al.,
2000; Dore, 2011). COX is a key enzyme in the
biochemical pathway leading to the synthesis of
prostaglandins, which are short-chain, lipid-derived
metabolites involved in a wide variety of physiological
processes and pathological conditions such as inflam-
mation and the development of neoplastic processes
(Dore, 2011). The oncogenic role of COX-2 may
occur as a result of its direct effect on cell proliferation
or indirectly due to the release and action of other cy-
tokines as suggested by their role in mitogenesis,
ovulation and development of kidney and bladder,
and/or as a pro-angiogenic factor (Khan et al., 2000;
Dore, 2011). Conversely, COX-1 is expressed consti-
tutively in the canine urinary bladder as it is respon-
sible for the production of prostaglandins involved in
maintaining homeostasis. Its expression appears not
to be affected by neoplastic transformation; the role
of COX-1 in the pathogenesis of urothelial tumours
remains unknown (Khan et al., 2000; Dore, 2011).
Inflammation and cancer are closely linked by spe-
cific oxidative processes in the tumour microenviron-
ment (Nowsheen et al., 2012). Consequently,
oxidative enzymes that are known to play a key role
in inflammation are increasingly being investigated
in connection with cancer (Morrison, 2012;
Wisastra and Dekker, 2014). Lipoxygenases (LOXs)
are oxidative enzymes, with a non-haem iron atom
in their active site, involved in the regulation of
inflammatory responses by generation of pro-
inflammatory mediators known as leukotrienes or
anti-inflammatory mediators known as lipoxins
(Wisastra and Dekker, 2014). LOXs and their degra-
dation products have been associated with tumour
cell proliferation, differentiation and apoptosis
(Wang and Dubois, 2010). Several LOXs have been
scrutinised, including LOX-5, LOX-12 and LOX-
15; however, recognition of the complexity of the
activation mechanism of LOX-5 has exposed
opportunities for further investigation into strategies
of inhibition (Wisastra and Dekker, 2014). The pro-
inflammatory effect of LOX-5 is predominantly asso-
ciated with the activation of nuclear factor ҡb (NFҡb)
(Wisastra and Dekker, 2014). In particular, the acti-
vation of LOX-5 leads to sustained angiogenesis
through induction of vascular endothelial growth fac-tor (VEGF), cell migration, invasion and resistance to
apoptosis, mediated by the inhibition of caspase 3
(Bishayee and Khuda-Bhuks, 2013). LOX-5 overex-
pression has been identified in various human
neoplastic diseases including, but not limited to, uro-
genital tumours such as prostatic, renal and bladder
cancer (Gupta et al., 2001; Hennig et al., 2002, 2005;
Jiang et al., 2003; Yoshimura et al., 2003;
Matsuyama et al., 2004; Hoque et al., 2005; Li et al.,
2005; Nathoo et al., 2006; Soumaoro et al., 2006;
Faronato et al., 2007; Melstrom et al., 2008; Yang
et al., 2012; Savari et al., 2013; Knab et al., 2015). In
man, LOX-5 overexpression has been observed
when comparing TCC with normal urinary bladder
tissue. Additionally, studies have reported a dose-
dependent growth inhibition of cancer cell lines
with the use of LOX-5 inhibitors (Yoshimura et al.,
2003; Hayashi et al., 2006; Matsuyama and
Yoshimura, 2009). In a study using transgenic mice
as a model, an increase in LOX-5 expression was
also correlated withmore aggressive TCC phenotypes
(Madka et al., 2014). The same study noted a dose-
dependent cancer growth reduction after treatment
with licofelone, a dual LOX/COX inhibitor, confirm-
ing previous findings (Madka et al., 2014).
Conversely, in veterinary oncology knowledge about
LOX-5 expression is limited to canine prostatic carci-
noma and osteosarcoma (Goodman et al., 2011;
Goupil et al., 2012). Naturally occurring canine
TCC closely mimics human invasive TCC, having
similar histopathological characteristics, molecular
features and biological behaviour (Knapp et al.,
2014).We hypothesised that LOX-5 has the potential
to be overexpressed in canine TCC relative to normal
tissue, therefore suggesting a potential role in patho-
genesis.
The primary aim of this study was to investigate the
immunohistochemical expression of LOX-5 in
normal canine urinary bladder, cystitis and TCC.
Secondarily, we analysed the relationships between
the expression of LOX-5, COX-1, COX-2 and
tumour location.Materials and Methods
Study Population
Tissue samples of canine cystitis and TCC, previously
submitted to the Department of Veterinary Pathol-
ogy and Public Health, University of Liverpool, Liv-
erpool, UK, were retrieved through a database
search. Original tissue sample collection took place
from January 2012 to December 2016. Cases were
considered eligible for the study only if sufficient
Lipoxygenase-5 Expression in Canine Urinary Bladder 3formalin fixed and paraffin wax-embedded (FFPE)
tissue was available for review.
Patient signalment and clinical data were retrieved
from the database of the Small Animal TeachingHos-
pital, University of Liverpool, Liverpool, UK, and via
telephone calls to the referring veterinarians. Dogs
were excluded from the study if they were known to
have received glucocorticoids, non-steroidal anti-in-
flammatory drugs (NSAIDs) and/or antineoplastic
chemotherapy prior to the tissue collection.
For dogs with a diagnosis of TCC, only subjects
know to have died of tumour-related causes were
enrolled in the study. For dogs diagnosed with cystitis,
only dogs with a histological diagnosis of inflamma-
tory urinary bladder disease, known to be alive 2
years after collection of tissue samples, were enrolled
in the study.
Due to the retrospective nature of the study and the
likelihood of variation among treatments offered to
each patient, data retrieved from the medical records
were restricted to standard signalment (i.e. sex, age,
breed and weight).
As a control group, normal urinary bladder tissue
was retrieved from the necropsy archive of the same
institution, enrolling only cases that died of no urinary
tract related causes and where no urinary tract pa-
thology was detected on histopathology. The study
was approved by the University of Liverpool Ethics
Committee (RETH000942).Histopathology and Immunohistochemistry
Histological slides were reviewed by a board-certified
veterinary pathologist (RV), blinded to the original
pathology report and the patient’s clinical data.
The slides had been prepared from FFPE tissues,
stained routinely with haematoxylin and eosin (HE)
and were observed under a bright-field upright mi-
croscope. TCCs were graded according to the adapt-
ed 2012World Health Organization (WHO) grading
system (Meuten and Meuten, 2017). Mitoses were
determined in an area of 2.37 mm2 (10 high-power
fields [HPFs], 400 with an ocular field number of
22).Table
Panel of antibodies used for
Antigen Antibody Type
LOX-5 ab103765 Rabbit polyclonal
COX-1 160108 Rabbit polyclonal
COX-2 Clone 33 Mouse monoclonal
LOX-5, lipoxygenase-5; COX-1, cyclooxygenase-1; COX-2, cyclooxygenRepresentative sections of the lesions were selected
for immunohistochemistry (IHC). Tissue sections
were dewaxed in xylene and hydrated through a series
of graded ethanol concentrations to distilledwater. An-
tigen retrieval was performed by calibrated water bath
capable of maintaining the epitope retrieval solution in
10 mM sodium citrate buffer (pH 6.0) at 97C for
30min. The sections were allowed to cool to room tem-
perature for 20 min. Endogenous peroxidase was
blocked using 100 ml Dako REAL peroxidase block-
ing solution for 10 min (Dako, Carpinteria, California,
USA). Tissue sections were incubated overnight with
the primary antibodies specific for LOX-5 (Abcam,
Cambridge, Massachusetts, USA), COX-1 (Cayman
Chemical, Ann Arbor, Michigan, USA) and COX-2
(BD Transduction Lab, San Jose, California, USA)
in a humid chamber at 4C; the antibodies were
selected according to the published literature (Khan
et al., 1998; Goodman et al., 2011; Campos et al.,
2014). Evaluation and validation of the optimal
concentration of each primary antibody were
performed with serial antibody dilutions (Table 1).
Labelling was ‘visualized’ by use of peroxidase conju-
gated polymer (EnVision FLEX Target Retrieval
Solution High pH, Tris/EDTA buffer pH 9; Dako)
for 30min and 3, 30 diaminobenzidine tetrahydrochlor-
ide was used as chromogen (DAB; Fisher Scientific,
Loughborough, UK). Sections were counterstained
withMayer’s haematoxylin.Asnegative serumcontrol,
mouse and rabbit unrelated sera were used instead of
the primary antibodies; control sections were treated
at the same time as sample sections. Positive tissue con-
trols are described in Table 1.
The distribution of immunohistochemical labelling
was scored as: 0, no positive cells; 1, 1e33% positive
cells; 2, 34e66% positive cells; 3, 67e100% positive
cells. Labelling intensity was scored as: 0, no positive
cells; 1, barely perceptible labelling if compared with
controls; 2, positive labelling, but weaker if compared
with controls; or 3, positive labelling relative to con-
trols. An IHC score was obtained by multiplying dis-
tribution by intensity for each antibody.
Immunohistochemical assessment of all three markers
was performed by avoiding any positive labelling of1
immunohistochemistry
Dilution Positive control
1 in 100 Canine leucocyte cell pellet
1 in 100 Normal canine kidney
1 in 800 Normal canine kidney (macula densa)
ase-2.
Fig. 1. Examples of LOX-5 immunohistochemical labelling intensity grades 1 (A, mild), 2 (B, moderate) and 3 (C, marked) in canine
urinary bladder TCC. Bars, 50 mm.
4 R. Finotello et al.inflammatory cells. Immunohistochemical results
were compared between normal epithelium, cystitis
samples and TCCs.Statistical Analysis
Correlations between LOX-5, COX-2 and COX-1 in-
tensity and distribution, LOX-5, COX-2 and COX-1
IHC score (score ¼ intensity  distribution) and age,
sex or weight between groups were analysed by use of
the Spearman’s test. Associations between LOX-5,
COX-2 and COX-1 IHC score and study groups, as
well as antibody expression and biopsy site (i.e.
body, apex or neck), were investigated by use of the
ManneWhitney U test. Statistical analysis was per-
formed using SPSS 13 Software (SPSS 13.0, SPSS
Inc., IBM Chicago, Illinois, USA).Results
Study Population
Twenty-nine TCCs of the urinary bladder, 13 cases of
cystitis and 10 normal urinary bladders fulfilled the
group-specific inclusion criteria and were included
in the study. For the purpose of the study, groups
were named as: ‘TCC’, ‘cystitis’ and ‘normal
bladder’.
In the TCC group (n ¼ 29) there were eight cross-
bred dogs, four Scottish terriers, three Labrador re-
trievers, two cocker spaniels and one each of golden
retriever, Rhodesian ridgeback, dachshund, minia-
ture schnauzer, fox terrier, Airedale, keeshond, do-
berman pincher, Bernese Mountain dog, Lhasa
Apso, English bulldog and Jack Russell terrier.
Twenty dogs were female (13 neutered, seven entire)
and nine were male (six neutered, three entire). With
regards to the site of biopsy, 18 were collected from
the neck, three from the apex and three from the
body of the urinary bladder; in five cases this informa-
tion was not specified and only ‘urinary bladder’ was
listed as the site of biopsy. The median age was 10years (range 4e16 years) and the median body
weight was 27 kg (range 6e42 kg). In eight cases, tis-
sue samples were collected by means of cystotomy/
partial cystectomy; the remaining 21 samples were
collected by means of cystoscopy (n ¼ 12) or
ultrasound-guided urinary catheter suction biopsy
(n ¼ 9).
In the cystitis group (n¼ 13) there were three cross-
bred dogs, three cocker spaniels and one each of
boxer, corgi, golden retriever, Scottish terrier, Shih
Tzu, Labrador retriever and bearded collie. All
dogs were female (four entire and nine neutered).
Themedian age was 6 years (3e11 years) and theme-
dian body weight was 20 kg (9e30 kg). All samples
were collected by means of cystoscopy.
In the normal bladder group there were two cross-
bred dogs and one each of cocker spaniel, golden
retriever, American Staffordshire terrier, pit bull,
fox terrier, doberman pincher, English bulldog and
Labrador retriever. Five dogs were female (three neu-
tered, two entire) and five were male (three neutered,
two entire). The median age was 6 years (3e11 years)
and the median body weight was 20 kg (9e30 kg).Histopathology
Transitional Cell Carcinoma Group. In the eight cases
collected by means of cystotomy/partial cystectomy,
TCC grading could be performed and all tumours
were graded as high-grade and invasive TCCs.
Among these, four had papillary and four had a
non-papillary pattern. In the remaining 21 samples,
collected by means of cystoscopy/ultrasound-guided
urinary catheter suction biopsy, cellularity was
considered as moderate to high in all samples, but
grade and invasiveness could not be assessed accu-
rately on the superficial biopsy samples. However,
two or more mitotic figures per HPF, mild to moder-
ate cellular atypia, including anisocytosis and aniso-
karyosis, nuclear abnormalities and prominent
nucleoli were observed in all samples; these features
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morphology. Of these 21 TCCs, differentiation was
attempted in 13 cases (10 papillary and three non-
papillary pattern).
Cystitis Group. All samples showed mild to moderate
inflammatory infiltration; this consisted of amixed in-
flammatory population composed of lymphocytes,
plasma cells and macrophages with no single inflam-
matory cellular component predominating. Occa-
sional presence of hyperplastic lymphoid follicles
with well-developed germinal centres (follicular
cystitis) was noted. In two samples, the mucosa was
ulcerated multifocally and this was associated with
the presence of both viable and degenerate neutro-
phils admixed with the inflammatory infiltrates.
Normal Bladder Group. No histological abnormalities
were noted as per inclusion criteria.Immunohistochemistry
Transitional Cell Carcinoma Group. Twenty-one of the
29 samples were suitable for immunohistochemical
investigation. LOX-5 was expressed in 20 out of 21
samples (95%), with a median IHC score of 2 (range
1e6). COX-2 was expressed in 19 out of 21 samples
(90%) with a median IHC score of 2 (range 1e9).
COX-1 was expressed in 20 out of 21 samples
(95%) with a median IHC score of 4 (range 1e6).
None of the samples was negative for more than one
antibody. Examples of LOX-5 labelling intensity
can be seen in Fig. 1.Fig. 2. Boxplots representing comparison of LOX-5 and COX-2 expr
dian. **P <0.01.Cystitis Group. LOX-5 was expressed in three out of
13 samples (23%) with a median IHC score of 1
(range 1e3). COX-2 was expressed in four out of 13
(31%) samples with amedian IHC score of 1.5 (range
1e4). Cases that were found to be positive for LOX-5
were negative for COX-2 and vice versa. COX-1 was
expressed in 12 out of 13 samples (92%) with a me-
dian IHC score of 3 (range 2e9). Only one sample
was negative for all three antibodies.
Normal Bladder Group. LOX-5 and COX-2 were ex-
pressed in only one out of 10 cases (10%; same case)
and both showed an IHC score of 1. COX-1 was ex-
pressed in all 10 cases (100%) with a median IHC
score of 2 (range 1e3). IHC findings of the three
groups are summarized in Table 2.
Comparative Analysis. LOX-5 and COX-2 immuno-
localization was similar among samples from the
cystitis and TCC groups, being mainly cytoplasmic
(>90% of positive neoplastic cells) with occasional
nuclear and cytoplasmic immunoreactivity (<10%).
COX-1 followed the same pattern with the majority
of cells (>90%) showing cytoplasmic immunolabel-
ling.
LOX-5 and COX-2 IHC scores were significantly
higher (P <0.01) in the TCC group compared with
the cystitis and normal bladder group (Fig. 2). The
LOX-5, COX-1 and COX-2 IHC score was not asso-
ciated with any signalment variable analysed, nor
there was correlation between LOX-5, COX-2 and
COX-1 distribution and intensity. The LOX-5 IHC
score was not affected by the biopsy site (apex versus
body versus neck).ession between groups. ManneWhitney U test; central value: me-
Table 2
Immunohistochemistry findings















TCC 21 20 1 (1e3) 2 (1e3) 2 (1e6) 19 2 (1e3) 1 (1e3) 2 (1e9) 20 2 (1e3) 1 (1e3) 4 (1e6)
Cystitis 13 3 1 1 (1e3) 1 (1e3) 4 1 (1e2) 1 (1e3) 1.5 (1e4) 12 1 (1e3) 3 (2e3) 3 (2e9)
Normal
bladder
10 1 1 1 1 1 1 1 1 10 1 2 (1e3) 2 (1e3)
IHC score ¼ intensity  distribution.
COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; LOX-5, lipoxygenase-5; TCC, transitional cell carcinoma.
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There has been exponential growth of research inves-
tigating the role of lipoxygenases in epithelial cancer
over the past two decades, both in human oncology
and to a lesser extent in canine models. Human
studies have demonstrated overexpression of LOX-5
in TCC compared with normal urinary bladder tis-
sue, where the degree of immunolabelling appears
to positively correlate with more aggressive TCC phe-
notypes (Matsuyama and Yoshimura, 2009; Madka
et al., 2014).
In the present study we investigated the immuno-
histochemical expression of LOX-5 in normal canine
urinary bladder epithelium and in cases of cystitis and
urothelial carcinoma, as these data were lacking in
the veterinary oncology literature. Results suggest
that normal canine urinary bladder epithelium usu-
ally lacks LOX-5 expression and that expression of
this enzyme is not constitutive for this organ. The
same lack of expression was observed for COX-2,
while COX-1 expression was found to be positive in
all normal samples; this is in agreement with previous
literature (Khan et al., 2000). In one case, all three
molecules were expressed weakly. This was an unex-
pected finding; however, it could be explained by
an aberrant expression of COX-2 and LOX-5 unique
to this patient or due to undetected urinary bladder
pathology. Aberrant enzymatic expression would be
most likely, given the normal histological findings
and the lack of urinary signs in this patient’s history.
This occurrence has not been reported previously in
dogs and is described rarely in man (Khan et al.,
2000; Yoshimura et al., 2001); however, normal
urinary bladder tissues are usually only used as
controls and the number of patients screened is
extremely low; it is therefore probable that
aberrations occur, but are less likely to be reported.
A predisposition towards developing urinary
bladder pathology could be hypothesized in this
scenario; however, as this was a necropsy sample,
assumptions are only speculative; moreover, nofollow-up information can be found in human litera-
ture (Yoshimura et al., 2001).
LOX-5 was expressed only in 23% of cases of
cystitis; COX-2 was also detected in a minority of pa-
tients (31%). Interestingly, these two enzymes were
not expressed simultaneously, suggesting a variable
activation of the arachidonic acid (AA) degradation
pathway in this condition. The findings in respect to
COX-2 are in disagreement with those reported by
Azuma et al. (2007) where COX-2 expression was
observed in the epithelium from 27 of 33 samples
(82%) of dogs with naturally occurring cystitis;
conversely, our results appear in alignment with find-
ings in cases of human chronic cystitis (Li et al., 2014).
The disparity between the findings of Azuma et al.
(2007) and the current study may be due to differ-
ences in patient selection and the possibility that
COX-2-positive inflammatory cells may have been
counted in the IHC analyses, contributing to the
greater number of positive patients.
In the TCC group, COX-2 was expressed in 90%
of the cases, in alignment with the present literature,
and LOX-5 was expressed in 95% of the samples
(Khan et al., 2000). For both antibodies the IHC score
was significantly higher in TCC compared with the
cystitis group and dual enzyme expression was a
consistent finding. Interestingly, LOX-5 and COX-
2 expression were not affected by the site of tumour bi-
opsy nor signalment data.
This study has several limitations, mainly due to its
retrospective nature and the collection of the majority
of cystitis and TCC samples by means of minimally
invasive procedures. It is possible, especially in the
TCC group, that the tissues collected were not fully
representative of the underling pathology; however,
given the strict inclusion criteria and the similarity
of our results with the human literature, chances of
misdiagnoses would appear low. As the majority of
the TCC samples were of the papillary subtype, asso-
ciation between tumour morphology and LOX-5
expression could not be investigated. Moreover,
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cystoscopy or ultrasound-guided urinary catheter
suction biopsy, resulting in diagnostic, yet small, tis-
sue samples that made evaluation of mitotic index
(among other tumour features) less accurate; this rep-
resents an undeniable limitation. Performing this
study on only cases of TCC diagnosed via surgical bi-
opsies would have potentially provided more infor-
mation. Such an approach is uncommon and can
only be reserved for selected cases (i.e. solitary lesions
amenable to resection, non-trigonal location) due to
the significant risk of bladder wall dehiscence and
neoplastic seeding of the surgical incision or abdom-
inal cavity (Knapp et al., 2014). Cystoscopy usually
provides better diagnostic samples compared with
traumatic catheterization. Such a difference was not
perceived in this study; however, this likely reflects
the inclusion criteria. It is the authors’ opinion that
cystoscopy biopsy sampling remains themost effective
method of establishing a diagnosis of TCC in canine
patients, as has been reported previously (Childress
et al., 2011).
Although the labelling intensity appeared rela-
tively similar to that reported in human studies, the
pattern of labelling observed was mainly cytoplasmic
in our cases compared with the more uniform cyto-
plasmic and nuclear distribution observed in human
tissues (Yoshimura et al., 2003; Matsuyama and
Yoshimura, 2009). This might have biological
relevance, as nuclear localization of LOX-5 is consid-
ered necessary for production of the lipid mediators
associated with proliferative activities, such as leuko-
triene B4 and 5-oxo-eicosatetraenoic acid. The lack/
paucity of nuclear LOX-5 immunolabelling has
been observed previously in canine osteosarcoma
and can be deduced from a study conducted on
canine prostatic pathologies (Goodman et al., 2011;
Goupil et al., 2012). Although at this stage we
cannot confirm the extent of the role of LOX-5 in
TCC development and progression, its (mainly) cyto-
plasmic localization could still represent a target for
therapy. In canine osteosarcoma, neoplastic cells un-
dergo apoptosis through caspase-3 activation, and
apoptosis is preceded by an increase in the formation
of reactive oxygen species, which appear to be related
to direct LOX-5 inhibition regardless of the cellular
localization (Loftus et al., 2016).
In conclusion, this study provides evidence that
LOX-5 is overexpressed in canine TCC and its inhibi-
tion should be evaluated by future studies as a possible
adjunctive treatment strategy. The therapeutic use of
LOX-5 inhibitors is supported by previous studies
conducted on human TCC, in which dose dependent
growth inhibition of cancer cell lines has been
achieved after treatment with LOX inhibitors(Yoshimura et al., 2003; Hayashi et al., 2006). The
same study demonstrated a dose dependent cancer
growth reduction in transgenic mice treated with
licofelone, a dual LOX-5/COX-2 inhibitor (Madka
et al., 2014).
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